ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2,1,Energy increased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2,2,Increased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
3,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3,2,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
3,3,Non-small cell lung cancer,Non-small cell neoplasms malignant of the respiratory tract cell type specified,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
3,4,Photopsia,Visual disorders NEC,Vision disorders,Eye,N
3,5,Therapy partial responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4,1,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
4,2,Immune-mediated enterocolitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
5,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
6,1,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
7,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
8,1,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
9,1,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
9,2,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
10,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
10,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
10,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
11,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
12,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
13,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
14,1,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
15,1,Osteonecrosis,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
16,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
16,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
17,1,Neutrophil count,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
18,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
19,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
20,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
21,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
21,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
21,3,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
22,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
23,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
23,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
23,3,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
24,1,Immune-mediated enterocolitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
25,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
25,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
25,3,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
25,4,Immune-mediated enterocolitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
26,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
26,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
26,3,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
26,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
27,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
27,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
27,3,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
27,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
27,5,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
28,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
28,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
28,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
28,4,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
28,5,Rebound effect,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
29,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
29,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
29,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
29,4,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
30,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
30,2,Connective tissue disorder,Connective tissue disorders NEC,Connective tissue disorders (excl congenital),Musc,N
30,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
30,4,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
31,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
32,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
33,1,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
33,2,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
34,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
35,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
35,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
36,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
37,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
38,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
38,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
38,3,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
39,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
40,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
41,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
42,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
42,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
43,1,Refusal of treatment by patient,Social issues NEC,Lifestyle issues,SocCi,N
44,1,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
45,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
46,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
46,2,Oxygen saturation decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
47,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
48,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
49,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
50,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
50,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
50,3,Spinal disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
51,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
51,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
51,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
51,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
51,5,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
51,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
51,7,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
51,8,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
52,1,Non-small cell lung cancer,Non-small cell neoplasms malignant of the respiratory tract cell type specified,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
53,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
54,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
55,1,Cardiac tamponade,Pericardial disorders NEC,Pericardial disorders,Card,Y
55,2,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
56,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
57,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
58,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
58,2,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
59,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
60,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
61,1,Blood sodium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
62,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
63,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
64,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
65,1,Non-small cell lung cancer,Non-small cell neoplasms malignant of the respiratory tract cell type specified,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
66,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
66,2,Optic neuritis,Optic nerve disorders NEC,Cranial nerve disorders (excl neoplasms),Nerv,N
67,1,Optic neuritis,Optic nerve disorders NEC,Cranial nerve disorders (excl neoplasms),Nerv,N
68,1,Drug effective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
68,2,Therapy partial responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
69,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
70,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
71,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
71,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
72,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
72,2,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
73,1,Intervertebral disc degeneration,Intervertebral disc disorders NEC,Musculoskeletal and connective tissue deformities (incl intervertebral disc disorders),Musc,N
